Fox News: New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

[riky]

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
     

TYKERB Demonstrates Activity in Combination with Other Targeted Therapies and as Monotherapy Across A Range of Breast Cancer Settings
- First Phase II data investigating the dual inhibition of HER2 and VEGF pathways with two oral, small molecule tyrosine-kinase inhibitors (TYKERB and pazopanib) demonstrates activity in first-line HER2 (ErbB2) positive breast cancer(1)
- Phase II results combining TYKERB and AVASTIN(R) (bevacizumab), a monoclonal antibody, shows activity in recurrent metastatic HER2-positive breast cancer(2)
- Final results from the largest prospective trial evaluating TYKERB monotherapy as a treatment for relapsed inflammatory breast cancer (IBC) demonstrates activity in this highly aggressive and difficult to treat disease(3)<img src="You are not allowed to view links. Register or Login" height="1" width="1"/><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
     

You are not allowed to view links. Register or Login